[go: up one dir, main page]

AR089507A1 - VARIANTES DE Fc DE INMUNOGLOBULINAS - Google Patents

VARIANTES DE Fc DE INMUNOGLOBULINAS

Info

Publication number
AR089507A1
AR089507A1 ARP120105031A ARP120105031A AR089507A1 AR 089507 A1 AR089507 A1 AR 089507A1 AR P120105031 A ARP120105031 A AR P120105031A AR P120105031 A ARP120105031 A AR P120105031A AR 089507 A1 AR089507 A1 AR 089507A1
Authority
AR
Argentina
Prior art keywords
variants
immunoglobulin
fcrn
binding affinity
immunoglobulins
Prior art date
Application number
ARP120105031A
Other languages
English (en)
Inventor
Lim Oh Euh
Ho Huh Yong
Youn Hwang Sang
Young Choi In
Chang Kwon Se
Youb Jung Sung
Original Assignee
Hanmi Science Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hanmi Science Co Ltd filed Critical Hanmi Science Co Ltd
Publication of AR089507A1 publication Critical patent/AR089507A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/283—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

Variantes de Fc de inmunoglobulinas que tienen una mayor afinidad de unión por el FcRn, caracterizadas por incluir una o más modificaciones de aminoácidos seleccionadas del grupo que consiste de 307S, 308F, 380S, 380A, 428L, 429K, 430S, 433K y 434S (esta numeración se basa en el índice EU) en la región constante de un fragmento de Fc de inmunoglobulinas nativas. Debido a la gran afinidad de unión por el FcRn, las variantes de Fc de inmunoglobulinas muestran una vida media in vivo más prolongada, y por consiguiente se pueden usar en la preparación de una formulación de acción prolongada de drogas proteicas. Conjugado de proteína.
ARP120105031A 2011-12-30 2012-12-27 VARIANTES DE Fc DE INMUNOGLOBULINAS AR089507A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
KR1020110147683A KR102041412B1 (ko) 2011-12-30 2011-12-30 면역글로불린 Ｆｃ 단편 유도체

Publications (1)

Publication Number Publication Date
AR089507A1 true AR089507A1 (es) 2014-08-27

Family

ID=48698034

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP120105031A AR089507A1 (es) 2011-12-30 2012-12-27 VARIANTES DE Fc DE INMUNOGLOBULINAS

Country Status (8)

Country Link
US (1) US20140357843A1 (es)
EP (2) EP3656792B1 (es)
JP (2) JP6448368B2 (es)
KR (1) KR102041412B1 (es)
CN (2) CN108465111A (es)
AR (1) AR089507A1 (es)
TW (2) TWI680137B (es)
WO (1) WO2013100702A1 (es)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20130049671A (ko) 2011-11-04 2013-05-14 한미사이언스 주식회사 생리활성 폴리펩타이드 결합체 제조 방법
JP6300121B2 (ja) * 2012-03-12 2018-03-28 ハンミ サイエンス カンパニー リミテッドＨａｎｍｉ Ｓｃｉｅｎｃｅ Ｃｏ．，Ｌｔｄ． 大腸菌細胞の高濃度培養方法
JP6538561B2 (ja) 2012-10-25 2019-07-03 バイオベラティブ・ユーエスエイ・インコーポレイテッド 抗補体Ｃ１ｓ抗体とそれらの用途
PT2914291T (pt) 2012-11-02 2022-05-05 Bioverativ Usa Inc Anticorpos anti-complemento c1s e suas utilizações
KR101895634B1 (ko) * 2013-05-31 2018-09-05 한미약품 주식회사 변이된 힌지 영역을 포함하는 IgG4 Fc 단편
AR096890A1 (es) * 2013-07-12 2016-02-03 Hanmi Pharm Ind Co Ltd Conjugando fc de inmunoglobulina, que mantiene la afinidad de unión del fragmento fc de la inmunoglobulina a fcrn
CN106103476B (zh) * 2013-12-24 2020-11-27 阿尔金克斯有限公司 FcRn拮抗剂及使用方法
BR112016020368A2 (pt) 2014-03-05 2018-01-23 Ucb Biopharma Sprl proteínas fc multiméricas
MX387560B (es) * 2014-03-31 2025-03-18 Hanmi Pharmaceutical Co Ltd Procedimiento para mejorar la solubilidad de proteínas y péptidos usando un enlace del fragmento fc de inmunoglobulina.
US20170029505A1 (en) * 2014-04-16 2017-02-02 Ucb Biopharma Sprl Multimeric fc proteins
CN104403004B (zh) * 2014-11-24 2017-10-13 苏州丁孚靶点生物技术有限公司 抗体‑干扰素异二聚体的制备和用途
EP4534107A3 (en) * 2015-09-24 2025-12-10 Hanmi Pharm. Co., Ltd. Protein complex by use of a specific site of an immunoglobulin fragment for linkage
AR107483A1 (es) * 2016-01-29 2018-05-02 Hanmi Pharm Ind Co Ltd Conjugado de enzimas terapéuticas
MA45602A (fr) 2016-07-08 2019-05-15 Staten Biotechnology B V Anticorps anti-apoc3 et leurs méthodes d'utilisation
CN106222129A (zh) * 2016-07-29 2016-12-14 广东东阳光药业有限公司 一种提高抗体纯度的细胞培养基和培养方法
WO2018032638A1 (zh) 2016-08-19 2018-02-22 安源医药科技（上海）有限公司 用于构建融合蛋白的连接肽
CN106279437B (zh) 2016-08-19 2017-10-31 安源医药科技（上海）有限公司 高糖基化人凝血因子viii融合蛋白及其制备方法与用途
CN106256835A (zh) * 2016-08-19 2016-12-28 安源医药科技（上海）有限公司 高糖基化人生长激素融合蛋白及其制备方法与用途
CN106317226B (zh) 2016-08-19 2017-09-05 安源医药科技（上海）有限公司 用于构建融合蛋白的连接肽
FI3525583T3 (fi) 2016-10-12 2025-10-31 Bioverativ Usa Inc Anti-c1s-vasta-aineita ja niiden käyttömenetelmiä
US11359001B2 (en) 2016-12-09 2022-06-14 Akston Biosciences Corporation Insulin-Fc fusions and methods of use
WO2018193427A1 (en) 2017-04-21 2018-10-25 Staten Biotechnology B.V. Anti-apoc3 antibodies and methods of use thereof
CN119390821A (zh) 2017-08-15 2025-02-07 伊兰科美国公司 兽药用IgG Fc变体
US10538583B2 (en) 2017-10-31 2020-01-21 Staten Biotechnology B.V. Anti-APOC3 antibodies and compositions thereof
JP7039694B2 (ja) 2017-10-31 2022-03-22 スターテン・バイオテクノロジー・ベー・フェー 抗ａｐｏｃ３抗体およびその使用方法
MX2020005981A (es) 2017-12-08 2020-08-24 Argenx Bvba Uso de antagonistas del fcrn para el tratamiento de la miastenia gravis generalizada.
WO2019235426A1 (ja) * 2018-06-04 2019-12-12 中外製薬株式会社 細胞質内での半減期が変化した抗原結合分子
MY209122A (en) 2018-06-08 2025-06-23 argenx BV Compositions and methods for treating immune thrombocytopenia
US11267862B2 (en) 2018-06-29 2022-03-08 Akston Biosciences Corporation Ultra-long acting insulin-Fc fusion proteins and methods of use
CN113038964B (zh) 2018-06-29 2025-05-27 德克拉有限公司 超长效胰岛素-fc融合蛋白及使用方法
EP3608674A1 (en) * 2018-08-09 2020-02-12 Regeneron Pharmaceuticals, Inc. Methods for assessing binding affinity of an antibody variant to the neonatal fc receptor
CA3138072A1 (en) 2019-06-07 2020-12-10 Argenx Bvba Pharmaceutical formulations of fcrn inhibitors suitable for subcutaneous administration
US20230027238A1 (en) * 2019-12-04 2023-01-26 Spectrum Pharmaceuticals, Inc. Methods of treatment using g-csf protein complex
FI4073098T3 (fi) 2019-12-19 2023-11-15 Akston Biosciences Corp Ultrapitkävaikutteiset insuliini-Fc-fuusioproteiinit ja niiden käyttömenetelmät
US11186623B2 (en) 2019-12-24 2021-11-30 Akston Bioscience Corporation Ultra-long acting insulin-Fc fusion proteins and methods of use
DK4087875T3 (da) 2020-01-08 2024-10-28 argenx BV Antagonister af human neonatal Fc-receptor (FcRn) til behandling af pemphigus-sygdomme
WO2021207599A1 (en) 2020-04-10 2021-10-14 Akston Biosciences Corporation Antigen specific immunotherapy for covid-19 fusion proteins and methods of use
US11192930B2 (en) 2020-04-10 2021-12-07 Askton Bioscences Corporation Ultra-long acting insulin-Fc fusion protein and methods of use
US11198719B2 (en) 2020-04-29 2021-12-14 Akston Biosciences Corporation Ultra-long acting insulin-Fc fusion protein and methods of use
JP2023526552A (ja) * 2020-05-22 2023-06-21 ハンミ ファーマシューティカル カンパニー リミテッド グルカゴン、ｇｌｐ－１及びｇｉｐ三重活性体の持続型結合体の液状製剤
US11981718B2 (en) 2020-05-27 2024-05-14 Ampsource Biopharma Shanghai Inc. Dual-function protein for lipid and blood glucose regulation
KR20220021890A (ko) * 2020-08-14 2022-02-22 한미약품 주식회사 삼중 활성체 지속형 결합체를 유효성분으로 포함하는 약학 조성물
WO2023004406A2 (en) 2021-07-23 2023-01-26 Akston Biosciences Corporation Insulin-fc fusion proteins and methods of use to treat cancer
JP2025520431A (ja) 2022-06-15 2025-07-03 アルジェニクス ビーブイ Ｆｃｒｎ／抗原結合分子及び使用方法
AU2024269873A1 (en) * 2023-05-10 2025-11-27 Macfarlane Burnet Institute For Medical Research And Public Health Limited Immunotherapeutic proteins
AU2024269644A1 (en) * 2023-05-10 2025-11-27 Macfarlane Burnet Institute For Medical Research And Public Health Limited Immunotherapeutic proteins

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6737056B1 (en) * 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
ES2727425T3 (es) * 2000-12-12 2019-10-16 Medimmune Llc Moléculas con semividas prolongadas, composiciones y usos de las mismas
US20040132101A1 (en) * 2002-09-27 2004-07-08 Xencor Optimized Fc variants and methods for their generation
US7361740B2 (en) * 2002-10-15 2008-04-22 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
US20050176108A1 (en) 2003-03-13 2005-08-11 Young-Min Kim Physiologically active polypeptide conjugate having prolonged in vivo half-life
JP2007531707A (ja) * 2003-10-15 2007-11-08 ピーディーエル バイオファーマ， インコーポレイテッド ＩＧの重鎖定常領域の位置２５０、３１４および／または４２８の変異誘発によるＦｃ融合タンパク質血清半減期の改変
CN101124245A (zh) * 2003-11-12 2008-02-13 比奥根艾迪克Ma公司 新生儿Fc受体(FcRn)-结合多肽变体、二聚体Fc结合蛋白及其相关方法
CA2545603A1 (en) * 2003-11-12 2005-05-26 Biogen Idec Ma Inc. Neonatal fc receptor (fcrn)-binding polypeptide variants, dimeric fc binding proteins and methods related thereto
RU2352583C2 (ru) * 2003-11-13 2009-04-20 Ханми Фарм. Инд. Ко., Лтд. ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ, СОДЕРЖАЩАЯ Fc-ОБЛАСТЬ ИММУНОГЛОБУЛИНА В КАЧЕСТВЕ НОСИТЕЛЯ
DK2213683T3 (da) * 2004-08-04 2013-09-02 Mentrik Biotech Llc VARIANT-Fc-REGIONER
EP2325206B1 (en) * 2004-11-12 2014-03-19 Xencor, Inc. Fc variants with altered binding to fcrn
US8367805B2 (en) * 2004-11-12 2013-02-05 Xencor, Inc. Fc variants with altered binding to FcRn
CN101098890B (zh) * 2004-11-12 2012-07-18 赞科股份有限公司 对FcRn的结合被改变的Fc变体
US8802820B2 (en) * 2004-11-12 2014-08-12 Xencor, Inc. Fc variants with altered binding to FcRn
US20070135620A1 (en) * 2004-11-12 2007-06-14 Xencor, Inc. Fc variants with altered binding to FcRn
US8163881B2 (en) * 2005-05-31 2012-04-24 The Board Of Regents Of The University Of Texas System Immunoglobulin molecules with improved characteristics
KR100824505B1 (ko) 2005-08-16 2008-04-22 한미약품 주식회사 개시 메티오닌 잔기가 제거된 면역글로불린 Ｆｃ 영역의대량 생산방법
JP2008169195A (ja) 2007-01-05 2008-07-24 Hanmi Pharmaceutical Co Ltd キャリア物質を用いたインスリン分泌ペプチド薬物結合体
ES2742268T3 (es) 2007-12-26 2020-02-13 Xencor Inc Variantes de Fc con unión alterada a FcRn
BRPI0914091B1 (pt) * 2008-10-14 2022-05-10 Genentech Inc Igg variante, composição farmacêutica, kit e usos de um igg variante
EP2233500A1 (en) * 2009-03-20 2010-09-29 LFB Biotechnologies Optimized Fc variants
TWI667257B (zh) * 2010-03-30 2019-08-01 中外製藥股份有限公司 促進抗原消失之具有經修飾的ＦｃＲｎ親和力之抗體
AR081066A1 (es) * 2010-04-02 2012-06-06 Hanmi Holdings Co Ltd Conjugado de insulina donde se usa un fragmento de inmunoglobulina
UA117901C2 (uk) * 2011-07-06 2018-10-25 Ґенмаб Б.В. Спосіб посилення ефекторної функції вихідного поліпептиду, його варіанти та їх застосування

Also Published As

Publication number Publication date
CN108465111A (zh) 2018-08-31
JP6689329B2 (ja) 2020-04-28
EP3656792C0 (en) 2024-07-03
TWI680137B (zh) 2019-12-21
JP6448368B2 (ja) 2019-01-09
CN104039831A (zh) 2014-09-10
KR102041412B1 (ko) 2019-11-11
EP2802604A4 (en) 2016-02-17
WO2013100702A1 (en) 2013-07-04
KR20130078633A (ko) 2013-07-10
JP2015507628A (ja) 2015-03-12
TW201336865A (zh) 2013-09-16
EP2802604A1 (en) 2014-11-19
JP2019001793A (ja) 2019-01-10
TW202012449A (zh) 2020-04-01
EP3656792B1 (en) 2024-07-03
EP3656792A1 (en) 2020-05-27
US20140357843A1 (en) 2014-12-04
CN104039831B (zh) 2018-02-23

Similar Documents

Publication Publication Date Title
AR089507A1 (es) VARIANTES DE Fc DE INMUNOGLOBULINAS
CY1122060T1 (el) Συνδυαστικη θεραπευτικη χρηση αντισωματων και ενδογλυκοσιδασεων
CY1124834T1 (el) Αναστολεις της αλληλεπιδρασης της μηνινης-mll
AR093803A1 (es) Composiciones y metodos de anticuerpos de marcaje de epo
EA201290964A1 (ru) Пептидные конъюгаты агонистов рецептора glp-1 и их применение
CY1120637T1 (el) Πολυπεπτιδικα αντισωματα που ανταγωνιζονται cd40
CY1119576T1 (el) Ν-ακυλ-(3-υποκατεστημενες)-(8-υποκατεστημενες)-5,6-διϋδρο-[1,2,4]τριαζολο[4,3-α]πυραζινες ως επιλεκτικοι ανταγωνιστες του υποδοχεα νκ-3, φαρμακευτικη συνθεση, μεθοδοι για χρηση σε διαμεσολαβουμενες απο τον υποδοχεα νκ-3 διαταραχες
EA201591908A1 (ru) Конденсированные гетероциклические соединения в качестве ингибиторов протеинкиназы
EA201391632A1 (ru) Аминокислотные последовательности, направленные против il-17a, il-17f и/или il-17a/f, и содержащие их полипептиды
EA201591176A1 (ru) Композиции и способы с использованием пептидной метки, связывающейся с гиалуронаном
CY1121335T1 (el) Anti-cxcr3 αντισωματα
PE20141019A1 (es) Nuevos inmunoconjugados
AR117911A2 (es) Anticuerpo anti-158p1d7 o fragmento de unión a antígeno del mismo, conjugado fármaco-anticuerpo, composición farmacéutica y sus usos
EA201490677A1 (ru) Связывающие антиген cd27l белки
EA201491569A1 (ru) МОДИФИЦИРОВАННЫЕ БИСПЕЦИФИЧЕСКИЕ АНТИТЕЛА IgG4 С СИММЕТРИЧНОЙ ПОСЛЕДОВАТЕЛЬНОСТЬЮ
AR101829A1 (es) Tratamiento de cáncer utilizando un receptor quimérico de antígeno cll-1
CR20140029A (es) Proteínas de unión a antígeno de tnf-alfa con unión a fcrn incrementada
UA118029C2 (uk) Модифіковане антитіло, що зв'язується з людським fcrn, й способи його застосування
EA201600190A1 (ru) Анти-prlr антитела и их применение
MX384191B (es) Molecula de union al antigeno especifico para el tejido objetivo.
EA201400579A1 (ru) Антитела к il-36r
EA201690325A1 (ru) БИСПЕЦИФИЧЕСКИЕ МОНОВАЛЕНТНЫЕ Fc-ДИАТЕЛА, КОТОРЫЕ СПОСОБНЫ СВЯЗЫВАТЬ CD32B И CD79b, И ИХ ПРИМЕНЕНИЯ
EA202193044A2 (ru) Способы лечения таупатии
EA201370178A1 (ru) Стабильные составы для парентеральной инъекции пептидных лекарственных средств
AR091649A1 (es) Optimizacion de anticuerpos que se fijan al gen de activacion de linfocitos 3 (lag-3) y sus usos

Legal Events

Date Code Title Description
FB Suspension of granting procedure